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accounts for 2% of all malignancies (1 ) . Patients with NEN often present with nonspecific symptoms and thus represent a major diagnostic challenge. There are several circulating NEN biomarkers, and chromogranin A (CgA) is regarded as the gold standard (2 ) . Chromogranin B (CgB) has been found to be a useful diagnostic addition to CgA measurements (3 ) . The peptide product of cocaine-and amphetamine-regulated transcript (CART) is also increased in patients with NENs, particularly in those with pancreatic NENs (4 ) .
Renal impairment or failure can increase circulating concentrations of CgA (2 ) and CART (4 ); however, CgB may be unaffected by mild renal impairment and is increased only in severe renal failure (3 ) . The population most likely to be affected by NEN is also susceptible to renal impairment: Chronic kidney disease (CKD) occurs in approximately 10% of the population between 50 and 60 years of age, and the mean age of patients with a NEN diagnosis is 61 years (1, 5 ) . We therefore examined the effect of varying degrees of renal impairment/failure on plasma concentrations of CgA, CgB, and CART in patients without NEN.
Ethics approval for this study was obtained from the Hammersmith and Queen Charlotte's and Chelsea Hospitals Research Ethics Committee (04/Q0406/80). After informed written consent was obtained, 5 mL of blood was collected from 40 healthy volunteers. In addition, samples from 107 patients with different stages of renal impairment were obtained and irreversibly anonymized as per Royal College of Pathology, UK, guidelines (D035, September 2007). All blood samples were collected into EDTA-containing tubes and centrifuged at 10 000g for 10 min within 15 min of venipuncture. Plasma samples were then stored at Ϫ20°C until analysis. CgA, CgB, and CART concentrations were measured by immunoreactivity (IR) (CgA-IR, CgB-IR, and CART-IR) with an in-house RIA (4 ) at the National Gut Hormone Specialist Assay and Advisory Laboratory, Imperial College Healthcare NHS Trust, UK.
To test for significant differences between healthy volunteers and individuals at different CKD stages, we analyzed the data by Kruskal-Wallis one-way ANOVA and adjusted for multiple comparisons with the Dunn test ( One-way ANOVA with Dunn a posteriori test compares groups of patients in different CKD stages against healthy volunteers for each biomarker. NS, not statistically significant (P Ͼ 0.05); *P ϭ 0.036; **P ϭ 0.026; ***P Ͻ 0. . The highest measured CART-IR concentration was 494 pmol/L (reference interval, Ͻ125 pmol/L).
The accuracy of GFR estimation decreases at near-normal levels of kidney function. Hence, consistent with common practice, normal eGFR values are reported as Ն60 mL ⅐ min Ϫ1 ⅐ ( ]. CgB is larger than CgA and CART and therefore may not be as dependent on glomerular filtration, which may explain the fewer cases of increased concentrations of CgB-IR among patients with renal disease.
Interestingly, no patients with renal failure had CgA-IR or CART-IR concentrations Ͼ500 pmol/L or CgB-IR concentrations Ͼ250 pmol/L. Therefore, although the diagnostic sensitivity of these NEN markers is low at these higher cutoffs (CgA-IR, 20% at 500 pmol/L; CART-IR, 17% at 500 pmol/L; CgB-IR, 12% at 250 pmol/L), the diagnostic specificity for NEN diagnosis is very high (100% for all 3 biomarkers). Patients with concentrations above these cutoffs must be investigated for NENs, even in the presence of renal failure. Our results indicate the need for additional studies to determine the diagnostic cutoffs with optimal sensitivity and specificity for the neuroendocrine biomarkers to enable NEN diagnosis in renally impaired patients.
